Atorvastatin‐Associated Liver Injury: Outcome After Statin Rechallenge
Our study evidenced frequent recurrence of drug-induced liver injury after atorvastatin rechallenge, whereas subsequent administration of a hydrophilic statin was well tolerated. By combining our data and published cases, we suggest that rosuvastatin or pravastatin carries the lowest risk of recurrence. Study limitations include a focus solely on atorvastatin, a retrospective design, and potential underreporting to the pharmacovigilance system.
Authors
- Anais Gaiffe (ORCID: https://orcid.org/0000-0003-3358-5650)
- Thierry Vial
- Blandine Bertin (ORCID: https://orcid.org/0000-0002-8655-3786)
- Virginie Lacotte (ORCID: https://orcid.org/0000-0002-6675-0686)
- J L Cracowski
Institutions
- Université Claude Bernard Lyon 1 (FR)
- Inserm (FR)
- Centre Hospitalier Universitaire de Besançon (FR)
- Hospices Civils de Lyon (FR)
- Hôpital Edouard Herriot (FR)
- Université Grenoble Alpes (FR)
- Université de Franche-Comté (FR)
Publication Details
- Journal
- Fundamental and Clinical Pharmacology
- Published
- 2026-02-15
- DOI
- https://doi.org/10.1111/fcp.70073
- Citations
- 1
- Primary Topic
- Lipoproteins and Cardiovascular Health
- Type
- article
- Field-Weighted Citation Impact
- 39.15